General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Tecartus (brexucabtagene autoleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Mantle cell lymphoma (MCL), relapsed or refractory, in adult patients who have received treatment with a Bruton's tyrosine kinase inhibitor (BTKi)
Last updated November 10, 2022
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated November 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Solid tumours in adult and pediatric patients that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.
Last updated November 7, 2022
Status:
Negotiations were not pursued
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Chronic weight management
Last updated October 25, 2022
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen, in adult patients
Last updated October 19, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated October 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Myelodysplastic Syndromes Associated Anemia
Last updated October 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Hepatic Encephalopathy
Last updated October 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Beta-Thalassemia Associated Anemia
Last updated October 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
High-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, in adult patients
Last updated October 7, 2022